The Unseen Struggle: Living with Premenstrual Dysphoric Disorder

Annika Waheed woke up to her sister's embrace after a suicide attempt. The morning her period began marked a shift in her eight-year battle with premenstrual dysphoric disorder (PMDD). "It felt like a switch," she said, describing how her ability to function returned. PMDD affects 3% to 8% of women of reproductive age globally. It causes intense irritability and suicidal thoughts, disrupting daily life and relationships. In 2019, the World Health Organization recognised PMDD as a distinct mental health disorder, yet public awareness remains low.

Annika's experience is not unique. A 2021 study published in JAMA Psychiatry revealed that 34% of women with PMDD attempted suicide at least once. The cyclical nature of PMDD complicates diagnosis, often leaving women untreated for years. "I thought I had bipolar disorder for most of my adult life because no one mentioned PMDD," Annika shared. Even after diagnosis, access to effective treatments varies. Options like hormone therapies and selective serotonin reuptake inhibitors (SSRIs) are often prescribed only during symptomatic days.

Dr. Tory Eisenlohr-Moul, a researcher at the University of Illinois Chicago, emphasised the importance of tracking symptoms over several months for diagnosis. "Understanding the timing of symptoms in relation to hormonal changes is key; this distinguishes PMDD from other psychiatric conditions," she said. Many healthcare providers lack the training to identify these patterns, leaving patients like Annika to navigate their condition largely unaided.

The economic and social costs of PMDD are significant. A 2018 analysis published in PLOS ONE estimated that women with PMDD lose an average of six days of work productivity per month. Relationships also suffer. "It’s like being two different people," Annika explained. "One week, I can be the partner and friend I want to be. The next, I isolate myself because I can’t trust my reactions."

Stigma surrounding menstrual health exacerbates these challenges, causing many women to suffer in silence. Advocacy groups like the International Association for Premenstrual Disorders (IAPMD) aim to change this narrative through education and destigmatisation. Progress is slow, especially in low- and middle-income countries where treatments are less accessible.

Research into PMDD's biological underpinnings is ongoing. Current findings suggest that women with PMDD have abnormal sensitivity to hormonal fluctuations, affecting brain areas linked to mood regulation. While genetics likely play a role, chronic stress may worsen symptoms.

Pharmaceutical development for PMDD has lagged. Most treatments are off-label and repurposed. One exception is GnRH agonists, which suppress ovarian function but are limited to severe cases due to side effects. "We need treatment options designed specifically for PMDD, not just borrowed from other areas of medicine," said Dr. Crystal Edler Schiller, a clinical psychologist at the University of North Carolina.

For Annika, joining a peer support group through the IAPMD transformed her experience. "Talking to women who understood what I was going through made me feel less alone," she said. Peer support has proven crucial for many, providing emotional relief and practical advice. However, without systemic changes, these individual efforts can only do so much.

Research and advocacy around PMDD are slowly gaining recognition, but gaps remain. Awareness campaigns must bridge the knowledge divide among healthcare providers and the public. More targeted funding could accelerate the development of treatments tailored to PMDD’s unique physiology. Until then, many women like Annika will continue to endure the cycle of despair and relief, waiting for a world that fully recognises their struggle.